FDA Approves Daratumumab for Transplant-Eligible Multiple Myeloma
On September 26, 2019, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex®) for adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant.
Ancestry Analysis Identifies Genetic Cause for Increased Multiple Myeloma in African Americans
Three cytogenetic subtypes are particularly responsible for the increased incidence of multiple myeloma in people of African descent, according to the results of a study published in Blood Cancer Journal.
Genetics Plays a Role in Treatment Response for Relapsed or Refractory Multiple Myeloma
No molecular-informed personalized therapies are currently available for patients with relapsed/refractory multiple myeloma (MM); however, cytogenetics and next-generation sequencing (NGS) can identify molecular abnormalities to provide guidance for more targeted therapy. Tarek Assi, MD, of Gustave Roussy Cancer Campus in Villejuif, France, discussed his research team’s findings that tumor genotyping is associated with higher response rates and prolonged duration of therapy at the ASH Annual Meeting on December 1, 2018.
Infection Linked to Early Mortality in Post-ASCT Multiple Myeloma
Patients with multiple myeloma are at increased risk for early death from infection after high-dose therapy and autologous stem cell transplantation (ASCT), according to the results of a study published in the American Journal of Hematology.
Multiple Myeloma Survivors Still Experience Symptoms and Psychological Concerns
Survival from multiple myeloma (MM) has improved, and more attention is required for symptom burden and psychological impact in the long-term management of this disease. Researchers assessed the incidence of self-reported pain, depression, financial and family burden, and impairment of performance status, as well as determined the correlation of total distress with survival. Joshua R. Richter, MD, at the John Theurer Cancer Center in Hackensack, NJ, discussed the findings at the ASH Annual Meeting.
Patients With MM Receiving PIs Need Herpes Zoster Prophylaxis
Patients with multiple myeloma (MM) who receive proteasome inhibitors (PIs) are at an increased risk for herpes zoster infection, and National Comprehensive Cancer Network guidelines recommend antiviral prophylaxis for these patients. Researchers examined the use of and adherence to antiviral agents in this patient population. Siyang Leng, MD, at Columbia University Medical Center in Sunnyside, New York, discussed the findings at the ASH Annual Meeting.
Manage Oncologic Emergencies With Multiple Myeloma
As new therapies come to market, patients with multiple myeloma have more treatment options that are improving outcomes and extending overall survival. However, the most effective options involve multidrug combinations and continuous maintenance therapy, which can result in cumulative toxicities and the potential for oncologic emergencies.
Bortezomib May Improve Outcomes in Multiple Myeloma
Adding bortezomib to combination therapy with lenalidomide and dexamethasone may improve progression-free and overall survival in patients with newly diagnosed multiple myeloma. The study findings were published in Lancet.
FDA Approves Lenalidomide as Maintenance Therapy for Patients With Multiple Myeloma
On February 22, 2017, the U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid®, Celgene Corp.) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
Statin Use May Improve Overall Survival From Multiple Myeloma
A new study has found that use of statin medications in patients with multiple myeloma was associated with a decreased risk of all-cause and cancer-specific mortality. The findings were published in the Journal of Clinical Oncology.